[Skip to Content]
[Skip to Content Landing]
Observation
November 2017

Canakinumab for Severe Hidradenitis Suppurativa: Preliminary Experience in 2 Cases

Author Affiliations
  • 1Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland
JAMA Dermatol. 2017;153(11):1195-1197. doi:10.1001/jamadermatol.2017.2392

Hidradenitis suppurativa is one of the most distressing conditions in dermatology with a remarkable negative effect on patients’ quality of life.1 Despite recent advances, there is still a great unmet need for effective long-term treatments for moderate and severe forms.1-3 Increased levels of cytokines associated with innate immunity, such as interleukin [IL]-1β, have been found in hidradenitis suppurativa skin samples.4 Canakinumab is a human IgGκ monoclonal antibody targeting IL-1β, and it modulates multiple proinflammatory and anti-inflammatory mediators. Therefore, canakinumab might represent an alternative treatment for hidradenitis suppurativa.2,3 We describe the efficacy of canakinumab in 2 patients with severe hidradenitis suppurativa (Hurley clinical stage III) who had poor response to standard treatment regimens.

×